2021. Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s56. DOI:https://doi.org/10.25251/skin.5.supp.56.